Trial Profile
A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400 mg Or 1000 mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tideglusib (Primary)
- Indications Myotonic dystrophy
- Focus Adverse reactions; Proof of concept
- Sponsors AMO Pharma
- 05 Jun 2021 Results published in the Pediatric Neurology
- 03 Mar 2021 According to an AMO Pharma media release, data from this study presented in the peer-reviewed journal Pediatric Neurology.
- 13 Jun 2019 Results published in the AMO Pharma Media Release.